Alecensa (alectinib) Letter of Medical Necessity
Alecensa (alectinib) is an oral ALK inhibitor for metastatic and resected ALK-positive NSCLC. Payers approve it quickly when the biomarker report, stage, and setting are documented, and deny it when they are not. A Letter of Medical Necessity should lead with the ALK result and the NCCN category.
FDA-Approved Indications
- ● ALK-positive metastatic non-small cell lung cancer
- ● adjuvant treatment after tumor resection of ALK-positive NSCLC (tumors 4 cm or larger or node-positive)
Why Alecensa Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. ALK rearrangement report not attached (FDA-approved test or NGS)
- 2. Stage, resection status, or line of therapy not documented
- 3. Specialty pharmacy network requirement not met
- 4. Preferred ALK inhibitor on formulary
- 5. Baseline liver function and CPK not documented
What to Include in a Alecensa Letter of Medical Necessity
Attach the ALK rearrangement report, staging and pathology (including resection and nodal status for the adjuvant setting), line of therapy, and baseline LFTs and CPK. Cite the NCCN recommendation and ALEX or ALINA data, and note CNS involvement where present as support for a CNS-penetrant ALK inhibitor.
Key clinical evidence to cite:
- ✓ ALEX Phase 3 trial — longer progression-free survival than crizotinib and strong CNS activity
- ✓ ALINA Phase 3 trial — improved disease-free survival vs platinum chemotherapy in resected ALK-positive NSCLC
- ✓ NCCN preferred first-line option for ALK-positive metastatic NSCLC
Relevant guidelines:
- 📖 NCCN Non-Small Cell Lung Cancer Guidelines
- 📖 ASCO/OH Therapy for Stage IV NSCLC with Driver Alterations
- 📖 ESMO Oncogene-Addicted Metastatic NSCLC Guideline
Alecensa Prior Authorization Criteria
Standard criteria across major US payers for Alecensa. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Alecensa
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Alecensa Prior Authorization FAQ
Why was my Alecensa prior authorization denied?
The most common denial reasons for Alecensa are: ALK rearrangement report not attached (FDA-approved test or NGS); Stage, resection status, or line of therapy not documented; Specialty pharmacy network requirement not met; Preferred ALK inhibitor on formulary; Baseline liver function and CPK not documented.
What should a Alecensa Letter of Medical Necessity include?
Attach the ALK rearrangement report, staging and pathology (including resection and nodal status for the adjuvant setting), line of therapy, and baseline LFTs and CPK. Cite the NCCN recommendation and ALEX or ALINA data, and note CNS involvement where present as support for a CNS-penetrant ALK inhibitor.
Which payers cover Alecensa?
Alecensa is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.